When the maker of a brand-name drug pays a maker of generic drugs to not produce a lower-priced version of their product, the Federal Trade Commission can challenge the arrangement on antitrust grounds, the Supreme Court ruled Monday. The ruling may end the era of what regulators call "pay-for-delay" deals.
The justices voted 5-3 to allow a case to go forward in which the FTC is challenging one of many such deals. Several companies are involved in the case, including Solvay Pharmaceuticals, maker of AndroGel, and generic-drug maker Actavis.
Let's look now at another change in health care, and this one has to do with paperwork. Hospitals and clinics are slowly replacing paper files with sophisticated electronic health records. But with a variety of systems in use, they often can't easily share medical information with each other, and this can be a pretty serious problem in the case of an emergency.
As Elizabeth Stawicki reports, smartphones might be one way to bridge this electronic gap.
Call it the Affordable Care Act, call it Obamacare, call it whatever you want — it's coming. And soon. In less than four months people without health insurance will be able to start signing up for coverage that begins Jan. 1.
A lot has been said about the law, most of it not that understandable. So starting now, and continuing occasionally through the summer and fall, we're going to try to fix that.